Abstract | OBJECTIVE: METHODS: All three patients met the Bohan and Peter diagnostic criteria for JDM. Intravenous pamidronate was given at 1 mg/kg/day on three consecutive days every three months according to the protocol established by Glorieux et al. for osteoporosis treatment in osteogenesis imperfecta. RESULTS: The calcinosis which developed in all three patients improved. No important adverse events were observed. CONCLUSION:
|
Authors | A Marco Puche, I Calvo Penades, B Lopez Montesinos |
Journal | Clinical and experimental rheumatology
(Clin Exp Rheumatol)
2010 Jan-Feb
Vol. 28
Issue 1
Pg. 135-40
ISSN: 0392-856X [Print] Italy |
PMID | 20346254
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Bone Density Conservation Agents
- Diphosphonates
- Pamidronate
|
Topics |
- Bone Density Conservation Agents
(administration & dosage, adverse effects)
- Calcinosis
(diagnostic imaging, drug therapy, etiology)
- Child
- Child, Preschool
- Dermatomyositis
(complications, diagnostic imaging, drug therapy)
- Diphosphonates
(administration & dosage, adverse effects)
- Female
- Humans
- Infant
- Injections, Intravenous
- Male
- Pamidronate
- Radiography
- Treatment Outcome
|